Rare Neurological Disease Treatment Market to Surpass US$12,000 Mn, with Heightened Investments in Orphan Drugs, Says FMI
According to a newly published Future Market Insights report, the global rare neurological disease treatment market will exhibit a splendid expansion throughout the forecast period (2017-2026). Revenues from the market are envisaged to exceed US$ 12,000 Mn by 2026-end.
New Drug Formulations and Initiatives toward Improving Treatment & Care of Patients to Influence Market Growth
Declining blockbuster drugs have led pharmaceutical companies to keenly investigate potential new areas of research & development. Drug manufacturers have been incentivized by the Orphan Drug Act to develop new drug formulations associated with treatment of various rare diseases such as rare neurological diseases, in a bid to introduce new treatment options to the market. Regulatory advantages such as breakthrough designations, longer market exclusivity, and reduced fees & tax incentives have encouraged investments in R&D of drugs related to rare neurological diseases.
The world is entering into a new era, wherein science has realized the capability of aiding development of treatment & care for patients affected with rare neurological conditions. Several initiatives are being taken for coordinating efforts of pharmaceutical companies and healthcare institutes who share similar aim of improving treatment & care for patients suffering from rare neurological diseases.
For example, Brains for Brain Foundation, European Brain Council, LSD Patient Collaborative, and members of pharma industry are supporting an initiative in Europe which is expected to enhance visibility, awareness and recognition of rare neurological disorders for facilitating their early diagnosis. The initiative also aims to facilitate and promote collaboration and partnership between physicians, patient advocates, decision- & policy-makers, and researchers.
For more insights into the Market, Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-6445
North America to Lead Global Rare Neurological Disease Treatment Market
North America is set to lead the global rare neurological disease treatment market, with an estimated revenue share of over 40% during 2017 to 2026. Economic and technological vigour, coupled with increasing geriatric population in the region, which is highly prone to such brain-related diseases, will influence demand for rare neurological disease treatment in North America.
The market revenue share of Europe and Asia-Pacific excluding Japan will also remain significant. However, combined revenues from the markets in these two regions will continue to be smaller than those amassed from the market in North America. Rare neurological disease treatment market in North America and Europe will record a parallel expansion through 2026, in terms of value.
Biologics to Remain Preferred Drug for Rare Neurological Disease Treatment
Biologics will continue to be the preferred drug for treatment of rare neurological diseases. Revenues from sales of biologics will account for the lion’s share of the market through the forecast period, based on drug type. However, revenues from sales of organic compounds for rare neurological disease treatment are forecast to record a relatively faster growth through 2026.
With an estimated market revenue share of nearly 60% during 2017 to 2026, Alzhiemer’s disease will continue to dominate the market, based on indication. In addition, revenues from treatment of this indication segment are likely to record the fastest rise in the market through 2026. Injectables will remain sought-after among mode of administration of drugs for treating rare neurological conditions.
Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-6445
Since the recent past, leading pharmaceutical companies have been placing more emphasis on rare disease, with tremendous support from the government. There is a greater likelihood that effective therapeutic measures for these life threatening rare diseases will be realized in the near future. FMI’s report identifies and tracks key players influencing expansion of the rare neurological disease treatment market that include EMD Serono, Inc., Jazz Pharmaceuticals, Teva Pharmaceutical Industries Limited, Johnson & Johnson, Sanofi, Medtronic Plc, Bayer Aktiengesellschaft, and Novartis AG.
More from FMI’s Healthcare, Pharmaceuticals and Medical devices Market Intelligence:
- Regenerative Medicine MarketRegenerative Medicine Market Segmentation by Technology – Stem Cell Therapy, Biomaterials, Tissue Engineering; by Applications – Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Bones, Autogenic Bones
- Industrial Microbiology MarketIndustrial Microbiology Market Segmentation By Product Type – Equipment and Systems, Reaction Consumables, and Laboratory Supplies; BY End User- Pharmaceutical and Biotechnology Companies, Food and Beverage Industry, Personal Care Products, Agriculture and Environment and Others
- Non-Surgical Fat Reduction MarketNon-Surgical Fat Reduction Market Segmentation by Product – Laser Based Devices , RF Devices, Ultrasound Devices, Other Devices; End User – Dermatology Clinics, Beauty Clinics
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org